Clozapine Re-challenge after NMS and Seizures in a Patient with DiGeorge

Austin Campbell, Pharm.D., BCPP
Clinical Pharmacy Specialist – Psychiatry
Adjunct Clinical Assistant Professor – Pharmacy
Adjunct Assistant Professor – Psychiatry
Disclosures

• Austin Campbell has no conflicts of interest to disclose for the session, nor will there be any off-label discussion of medications.
Objectives

1. Discuss the clinical presentation of DiGeorge Syndrome and its association with schizophrenia

2. Identify the complications of treating schizophrenia in patients with DiGeorge

3. Review available evidence supporting clozapine rechallenge after serious adverse effects
Case

- 25 year old Caucasian male
- Admitted to acute psychiatric hospital for worsening aggression, auditory and visual hallucinations, suicidal and homicidal ideations
- History of:
  - Moderate intellectual disability
  - Schizophrenia – diagnosed age 15
  - DiGeorge syndrome – diagnosed age 16
Case

- **Medications Day 1:**
  - Fluphenazine 5 mg QID
  - Olanzapine 25 mg HS
  - Quetiapine 500 mg HS
  - Clonazepam 1 mg TID
  - Temazepam 30 mg HS
  - Citalopram 10 mg daily
  - Divalproex ER 500 mg AM & 1000 mg HS

- **Medications Day 16:**
  - Fluphenazine 5 mg TID
  - Divalproex ER 500 mg AM & 1000 mg HS
  - Clozapine 100 mg AM & 200 mg HS
Case

• Day 16
  – Temperature 105.2 °F
  – Creatine Kinase > 1100 units/L
  – Tremors and mild rigidity
  – Transferred to ICU where diagnosed with neuroleptic malignant syndrome (NMS)
  – Began 14 day washout

• Day 19
  – Moved from ICU to medicine unit

• Day 24
  – Transferred back to psychiatry
  – Experienced tonic-clonic seizure
DiGeorge Syndrome (DGS)

- 22q11.2 deletion syndrome (22qDS)
- Most common microdeletion syndrome
  - Estimated frequency 1:2000 to 1:4000 live births
- Roughly 3 million base deletion
- Highly variable: >180 clinical features described
- Common features: “CATCH 22”
  - Conotruncal cardiac anomalies
  - Abnormal face
  - Thymic hypoplasia
  - Cleft palate
  - Hypocalcemia

<table>
<thead>
<tr>
<th>Non-immunologic Clinical Findings</th>
<th>Percent (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palatal Anomalies</td>
<td>69 – 100</td>
</tr>
<tr>
<td>Speech Delay</td>
<td>79 – 90</td>
</tr>
<tr>
<td>Learning Disabilities</td>
<td>45 – 90</td>
</tr>
<tr>
<td><strong>Cardiac Abnormalities</strong></td>
<td><strong>49 – 83</strong></td>
</tr>
<tr>
<td>Developmental Delay</td>
<td>75</td>
</tr>
<tr>
<td>Ophthalmologic Abnormalities</td>
<td>7 – 70</td>
</tr>
<tr>
<td><strong>Hypocalcemia</strong></td>
<td><strong>17 – 60</strong></td>
</tr>
<tr>
<td>Psychiatric Disorders</td>
<td>9 – 60</td>
</tr>
<tr>
<td>Skeletal Abnormalities</td>
<td>17 – 45</td>
</tr>
<tr>
<td>Renal Abnormalities</td>
<td>31 – 37</td>
</tr>
</tbody>
</table>

Adapted from: DiGeorge (22q11.2 deletion) syndrome  In: Basow DS, ed. *UpToDate*. Accessed 2/21/2017
DGS and Schizophrenia

• Nearly 1/3 of individuals with 22qDS develop schizophrenia
  – Prevalence in schizophrenia: 1:100
• Represents the most highly replicated schizophrenia subtype
  – Possibly the first identifiable genetic subtype
• No specific treatment recommendations for schizophrenia management
  – Standard approaches suggested

Case: What went wrong?
• Retrospective long-term safety and efficacy study conducted in Canada
• Evaluated clozapine in 40 patients with schizophrenia
  – 20 patients with 22qDS and 20 controls matched for age and severity
  – All confirmed with molecular testing
• Used medical records, extensive clinical histories, and semi-structured interviews
Results

- Both groups demonstrated improvement on CGI-I scale (p=0.33)
- Both experienced significant reductions in hospitalization
- Median maintenance dose significantly lower in 22qDS group – 250 mg vs. 400 mg

Butcher NJ. Br J Psychiatry. 2015; 206(6):484
## Results

<table>
<thead>
<tr>
<th>Adverse Effect</th>
<th>22qDS, n (%)</th>
<th>Control, n (%)</th>
<th>Novartis trials (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedation</td>
<td>15 (75)</td>
<td>14 (70)</td>
<td>39</td>
</tr>
<tr>
<td>Weight gain</td>
<td>10 (50)</td>
<td>7 (35)</td>
<td>31</td>
</tr>
<tr>
<td>Hypersalivation</td>
<td>10 (50)</td>
<td>9 (45)</td>
<td>31</td>
</tr>
<tr>
<td>Dizziness</td>
<td>9 (45)</td>
<td>3 (15)</td>
<td>19</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>5 (25)</td>
<td>6 (30)</td>
<td>25</td>
</tr>
<tr>
<td><strong>Seizures</strong></td>
<td>8 (40)</td>
<td>0 (0)</td>
<td>3</td>
</tr>
<tr>
<td><strong>Neutropenia</strong></td>
<td>3 (15)</td>
<td>0 (0)</td>
<td>&lt; 3</td>
</tr>
<tr>
<td><strong>Myocarditis</strong></td>
<td>1 (5)</td>
<td>0 (0)</td>
<td>0.06</td>
</tr>
</tbody>
</table>

To date, no case had been reported in a patient with DGS-associated schizophrenia

Estimated incidence NMS 0.02% - 0.03%

Mortality estimated 5.6 – 20%

Risk factors include:

- **High potency drugs**, parenteral administration, rapid dose escalation, **polypharmacy**, **other CNS disorders**, dehydration

Risk of recurrence as high as 30% when rechallenged with same agent

Citrome L. *Clinical Schizophrenia & Related Psychosis*. Fall 2016
Clozapine & NMS

• May have an atypical presentation
  – Fever or muscle rigidity vs. having both
• > 20 cases of clozapine-associated NMS reported in literature
• Few provide information on successful rechallenge or rechallenge strategies

Citrome L. *Clinical Schizophrenia & Related Psychosis*. Fall 2016
Anbalagan E. *Psychiatr Q*. 2014; 85:345
Shedlack KJ. *Harv Rev Psychiatry*. 2003; 11:334
Rechallenge Principles

• If possible, recommend wash-out period of at least 14 days after NMS symptom resolution
  – Rechallenge has occurred within 5 days for patients experiencing intolerable effects due to antipsychotic discontinuation
• Reevaluate patient risk factors and modify if possible
• Utilize the “low and slow” method
• Consider alternative antipsychotic

Citrome L. Clinical Schizophrenia & Related Psychosis. Fall 2016
Anbalagan E. Psychiatr Q. 2014; 85:345
Shedlack KJ. Harv Rev Psychiatry. 2003; 11:334
Case

• Days 31 – 32
  – Patient transferred back to psychiatry on Divalproex ER only
  – Persistent hallucinations and aggressive behavior
  – Case conference and family meeting held
  – Clozapine restarted at 12.5 mg

• Day 61
  – Clozapine 137.5 mg/day (Clozapine = 319, Norclozapine = 89)
  – Patient brighter, able to participate in interview, hallucinations reduced
  – Discharged: Described as “brighter”
"What's right is what's left if you do everything else wrong."
- Robin Williams